The MarketReader Minute
đź’Š Biotech ETF Climbs as FDA Approvals and Positive Trial Results from Cytokinetics, Ionis, Biogen Drive Gains | Biotech Sector Insights
IBB advanced with notable contributions from Cytokinetics, Ionis, and Biogen, supported by fresh approvals and positive clinical data. Eupraxia’s trial news added momentum, offsetting recent weekly weakness and lifting year-to-date gains to 4.6%.